$DYAI News

Dyadic International 13G Filing Shows Empery Asset Management Reports 8.35% Stake In Co. As Of Sept. 30

Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Dyadic International (DYAI) Q2 2026 Earnings Call Transcript

DYAI: Second Quarter Results

Dyadic International, Inc. Q2 2026 Earnings Call Summary

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

Dyadic International Announces Definitive Agreements For $2.9M Registered Direct Offering And Concurrent Private Placement Of Warrants With Institutional Investor

Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ...

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic International Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $961.138K Miss $993.333K Estimate

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

Dyadic International Inks New Development, Commercial License Agreement With European Biotechnology Firm For Additional Precision Fermented Dairy Proteins

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic International Regains Nasdaq Compliance

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Dyadic Expands IP Protection and Business Development Activities in Japan